Application of BMH-21 in preparation of antihypertensive drugs
The RNA polymerase I inhibitor BMH-21 inhibits ribosome biosynthesis and reduces the expression of smooth muscle cell-related proteins, solves the problem of low therapeutic effect of existing anti-hypertensive drugs, achieves effective blood pressure reduction, and provides new clinical practice treatment plan.
Patent Information
- Application Number
- CN202411165041.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing anti-hypertensive drugs have low therapeutic effects, poor compliance, and large adverse drug reactions. They have failed to effectively control the hypertension conditions of more than 1 billion people around the world, resulting in high incidence of cardiovascular diseases such as heart disease and stroke and huge economic burden. .
Developed the RNA polymerase I inhibitor BMH-21 to reduce the expression of relevant proteins in smooth muscle cells by inhibiting the process of ribosome biosynthesis, thereby reducing blood pressure. BMH-21 is used to combine with pharmaceutically acceptable carriers to prepare anti-anti-dose forms of different dosage forms. Hypertensive medication.
BMH-21 effectively inhibits the biosynthesis of ribosomes in smooth muscle cells and lowers blood pressure, providing new anti-hypertensive drugs, has good clinical application value and broad prospects, and can be used to treat primary and salt-sensitive hypertension.
Smart Images

Figure CN119015288A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to application of BMH-21 in preparing antihypertensive drugs, belonging to the technical field of biomedicine. Background Art
[0002] Hypertension refers to a clinical syndrome characterized by increased systemic arterial blood pressure (systolic and / or diastolic blood pressure) (systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg), which may be accompanied by functional or organic damage to organs such as the heart, brain, and kidneys. Currently, hypertension is an important factor in the global disease burden, affecting more than 1 billion people internationally. At the same time, hypertension is also one of the main causes behind coronary heart disease, stroke, and various other cardiovascular diseases that may lead to death. Despite relatively comprehensive treatments for hypertension, less than one-fifth of patients worldwide have their condition effectively controlled. Therefore, in-depth research on the pathogenesis and progression of hypertension and the development of targeted treatment strategies based on individual needs are increasingly attracting attention.
[0003] At present, antihypertensive drugs include more than 60 drugs in 15 categories, such as diuretics, calcium channel blockers (CCBs), beta-blockers and angiotensin II receptor antagonists, but they still face various difficulties, such as low patient treatment rate, poor compliance, low compliance rate, large adverse drug reactions, and easy drug resistance. Therefore, hypertension still causes at least 45% of heart disease deaths and 51% of stroke deaths worldwide each year, causing losses of more than 250 billion US dollars, and has become one of the most serious public health problems in the world, so it is urgent to develop new drugs that are safe and effective for the treatment of hypertension.
[0004] Ribosome biogenesis is the process of ribosome production, including the transcription of ribosomal RNA (rRNA), the processing of rRNA precursors, and the assembly of ribosomal subunits. Under the action of RNA polymerase I (RNA Pol I), SL1 (selectivity factor), UBF (upstream binding factor), and TIF-1A (RRN3; transcription initiation factor IA), ribosomal DNA is transcribed into 47Spre-rRNA, which is a rate-limiting step in the entire biological process and is determined by the activity of RNA Pol I. Ribosome dysfunction can cause myocardial hypertrophy and myocardial infarction, and excessive activation of ribosome biogenesis can also lead to abnormal proliferation of smooth muscle cells and the occurrence of atherosclerosis. Therefore, the development of RNA Pol I inhibitors may be a new idea for the treatment of cardiovascular diseases.
[0005] RNA Pol I inhibitor BMH-21 is a new type of compound based on high-throughput screening of cells, and its derivatives are currently in the preclinical development stage. BMH-21 destroys RNA Pol I and triggers its degradation, which in turn leads to the obstruction of ribosome biosynthesis. As the nucleolus becomes an emerging target for cancer treatment, BMH-21 has received widespread attention in the field of cancer, but there are no reports on its relationship with hypertension and its effect on hypertension, and there are no reports on the use of BMH-21 in the treatment of hypertension. Summary of the invention
[0006] In view of the deficiencies of the prior art, the present invention provides the use of BMH-21 in the preparation of antihypertensive drugs.
[0007] The technical solution of the present invention is as follows:
[0008] The invention provides application of BMH-21 in preparing antihypertensive drugs.
[0009] The structural formula of BMH-21 is as follows:
[0010]
[0011] Preferably according to the present invention, the hypertension is essential hypertension or salt-sensitive hypertension.
[0012] Preferably according to the present invention, the antihypertensive drug inhibits the synthesis of 47S pre-rRNA, 18SrRNA, 28SrRNA and 5.8S rRNA in smooth muscle cells, reduces the expression levels of myocardin (MYOCD), serum response factor (SRF) and myosin light chain kinase (MYLK) in smooth muscle cells, thereby lowering blood pressure.
[0013] Preferably according to the present invention, the antihypertensive drug contains a pharmaceutically effective dose of BMH-21 and a pharmaceutically acceptable carrier.
[0014] Further preferably, the pharmaceutically acceptable carrier is a mixture of one or more of skim milk, lactose, glucose, sucrose, sorbitol, mannose, trehalose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate or mineral oil.
[0015] Preferably according to the present invention, the antihypertensive drug can be in any one or more pharmaceutically feasible dosage forms, including but not limited to tablets, pills, injections, capsules, oral solutions or lyophilized powders.
[0016] The beneficial effects of the present invention are:
[0017] 1. The present invention first discovered the key role of RNA Pol I inhibitor BMH-21 in hypertension. BMH-21 can effectively inhibit the ribosome biosynthesis process in smooth muscle cells, reduce the expression levels of smooth muscle cell contraction-related proteins MYOCD, SRF and MYLK, and thus reduce blood pressure. Therefore, the present invention provides a new use of RNA Pol I inhibitor BMH-21 in the preparation of antihypertensive drugs, provides a new antihypertensive drug for clinical use, and has good clinical application value and broad application prospects.
[0018] 2. The RNA Pol I inhibitor BMH-21 of the present invention can be used to play a key role in hypertensive diseases and can be prepared into the form of drugs, pharmaceutical compositions, foods, health products or food additives. The drugs, pharmaceutical compositions, foods, health products or food additives contain BMH-21. These drugs, pharmaceutical compositions, foods, health products or food additives can be used to treat hypertensive diseases including essential hypertension and salt-sensitive hypertension, and have important application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is a curve of continuous changes in blood pressure after intraperitoneal injection of BMH-21 in spontaneously hypertensive rats (SHR);
[0020] In the figure, SHR represents spontaneously hypertensive rats, SHR+Vehicle represents spontaneously hypertensive rats intraperitoneally injected with control solvent, SHR+BMH-21 represents spontaneously hypertensive rats intraperitoneally injected with BMH-21 drug, SBP represents systolic blood pressure, MBP represents mean arterial pressure, and DBP represents diastolic blood pressure.
[0021] Figure 2 The ribosome biosynthesis was detected by RT-PCR in aorta tissues obtained from spontaneously hypertensive rats (SHR) after intraperitoneal injection of BMH-21.
[0022] In the figure, Vehicle represents spontaneously hypertensive rats injected with a control solvent, and BMH-21 represents spontaneously hypertensive rats injected with a BMH-21 drug.
[0023] Figure 3 The expression of smooth muscle contraction-related proteins in primary aortic smooth muscle cells of C57BL / 6J mice after intervention with BMH-21;
[0024] In the figure, A is a Western blot verification diagram of contraction-related proteins in smooth muscle cells; B is a statistical diagram of the expression level of Figure A; β-actin is a protein internal reference. DETAILED DESCRIPTION
[0025] The present invention is further described below in conjunction with the examples, which are only used to illustrate the present invention, but not to limit the scope of protection of the present invention. The drugs and reagents involved in the examples are all common commercially available products unless otherwise specified; the experimental operations involved in the examples are all carried out according to conventional operations in the art unless otherwise specified.
[0026] The spontaneously hypertensive rats (SHR) used in the embodiments of the present invention are obtained by mating a male Wistar Kyoto rat with a systolic blood pressure of 150-175 mmHg with a female Wistar Kyoto rat with a systolic blood pressure of 130-140 mmHg, and obtaining offspring with a systolic blood pressure greater than 150 mmHg. Then, rats with higher blood pressure are selected for inbreeding. This selective inbreeding is carried out for 20 generations in sequence to obtain stable hypertension inheritance, thereby establishing the SHR variety. In addition to spontaneous hypertension, this rat also has hypertensive cardiovascular disease. Among various genetically hypertensive rats, SHR is the most widely used. The increase in blood pressure of SHR is determined by polygenic inheritance, which is very similar to human hypertension. It is an ideal animal model for studying the pathogenesis of hypertension and screening antihypertensive drugs. The SHR rat is available at Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.
[0027] The RNA polymerase I inhibitor BMH-21 is available from Selleck.
[0028] Example 1: Intraperitoneal injection of BMH-21 reduces blood pressure in spontaneously hypertensive rats (SHR)
[0029] 10-week-old male SHR were intraperitoneally injected with BMH-21, and the solvent injection group was used as a control, that is, the SHR was divided into two groups: ① Vehicle (control group); ② BMH-21 (experimental group). The rats were intraperitoneally injected with BMH-21 at a dose of 35 mg / kg for 6 consecutive days, and the blood pressure changes were continuously monitored. The continuous change curves of the blood pressure of the two groups of rats were recorded. The results are shown in the figure. Figure 1 shown.
[0030] After a significant difference in blood pressure was observed, the rats were euthanized and aortic tissue was obtained. The biosynthesis of 47S pre-rRNA, 18S rRNA, 28S rRNA, and 5.8S rRNA in aortic smooth muscle cells was detected by RT-PCR. The results were as follows Figure 2 shown.
[0031] Depend on Figure 1 It can be seen that compared with the control group, the blood pressure of SHR decreased significantly after intraperitoneal injection of BMH-21.
[0032] Depend on Figure 2 It can be seen that compared with the control group, the synthesis of 47S pre-rRNA in smooth muscle cells of the experimental group was significantly reduced, and the 18S, 28S and 5.8S rRNA generated by 47S pre-rRNA processing were also significantly lower than those in the control group.
[0033] Combination Figure 1 and Figure 2 It can be seen that intraperitoneal injection of BMH-21 can significantly inhibit the synthesis of 47S pre-rRNA, 18SrRNA, 28S rRNA and 5.8S rRNA in smooth muscle cells, thereby lowering the blood pressure of SHR.
[0034] Example 2: BMH-21 reduces the expression of smooth muscle contraction-related proteins
[0035] Primary smooth muscle cells were isolated from C57BL / 6J mice and then cultured in 37°C, 5% CO 2 The cells were cultured to the exponential phase under the conditions, and BMH-21 (final concentration 0.5 μM) was added for co-culture for 24 hours. The cells were then ground after adding protein lysis buffer to obtain smooth muscle cell protein. 15 μg of protein was loaded for Western blot verification to detect the expression of smooth muscle cell contraction-related proteins MYOCD, SRF, and MYLK. The results are shown in Figure 3 shown.
[0036] Depend on Figure 3 It can be seen that BMH-21 can significantly reduce the expression levels of smooth muscle cell contraction-related proteins MYOCD, SRF and MYLK, thereby reducing the contractile ability of smooth muscle cells and thus lowering blood pressure.
[0037] The above results confirm the key role of BMH-21 in lowering blood pressure: by intraperitoneal injection of BMH-21 into spontaneously hypertensive rats, the synthesis of 47S pre-rRNA, 18S rRNA, 28S rRNA and 5.8SrRNA in smooth muscle cells can be effectively inhibited, and the expression levels of smooth muscle cell contraction-related proteins MYOCD, SRF and MYLK can be reduced, thereby lowering the blood pressure of spontaneously hypertensive rats, providing a new antihypertensive drug for clinical use, with good clinical application value and broad application prospects.
Claims
1. Application of BMH-21 in the preparation of antihypertensive drugs, It is characterized in that The structural formula of BMH-21 is as follows:
2. The use according to claim 1, It is characterized in that The hypertension is essential hypertension or salt-sensitive hypertension.
3. The use according to claim 1, It is characterized in that The antihypertensive drug inhibits the synthesis of 47S pre-rRNA, 18S rRNA, 28S rRNA and 5.8S rRNA in smooth muscle cells, reduces the expression levels of myocardin, serum response factor and myosin light chain kinase in smooth muscle cells, thereby reducing blood pressure.
4. The use according to claim 1, It is characterized in that The antihypertensive drug contains a pharmaceutically effective dose of BMH-21 and a pharmaceutically acceptable carrier.
5. The use according to claim 4, It is characterized in that The pharmaceutically acceptable carrier is a mixture of one or more of skim milk, lactose, glucose, sucrose, sorbitol, mannose, trehalose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate or mineral oil.
6. The use according to claim 1, It is characterized in that The antihypertensive drug may be in any one or more pharmaceutically feasible dosage forms, including but not limited to tablets, pills, injections, capsules, oral solutions or lyophilized powders.
Citation Information
Patent Citations
Application of RNA polymerase I inhibitor in inhibition of restenosis
CN106822900A
